BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 30282070)

  • 1. Promoter Methylation of Ezrin and its Impact on the Incidence and Prognosis of Cervical Cancer.
    Qin R; Cao L; Wang J; Liu J
    Cell Physiol Biochem; 2018; 50(1):277-287. PubMed ID: 30282070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High expression of ezrin predicts poor prognosis in uterine cervical cancer.
    Kong J; Li Y; Liu S; Jin H; Shang Y; Quan C; Li Y; Lin Z
    BMC Cancer; 2013 Nov; 13():520. PubMed ID: 24182314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of ezrin and galectin-3 as predictors of poor prognosis of cervical cancer.
    Li M; Feng YM; Fang SQ
    Braz J Med Biol Res; 2017 Mar; 50(4):e5356. PubMed ID: 28355349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ezrin and E-cadherin expression profile in cervical cytology: a prognostic marker for tumor progression in cervical cancer.
    Zacapala-Gómez AE; Navarro-Tito N; Alarcón-Romero LDC; Ortuño-Pineda C; Illades-Aguiar B; Castañeda-Saucedo E; Ortiz-Ortiz J; Garibay-Cerdenares OL; Jiménez-López MA; Mendoza-Catalán MA
    BMC Cancer; 2018 Mar; 18(1):349. PubMed ID: 29587669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and significance of Six1 and Ezrin in cervical cancer tissue.
    Tan J; Zhang C; Qian J
    Tumour Biol; 2011 Dec; 32(6):1241-7. PubMed ID: 21874375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serine/threonine kinases 31(STK31) may be a novel cellular target gene for the HPV16 oncogene E7 with potential as a DNA hypomethylation biomarker in cervical cancer.
    Yin FF; Wang N; Bi XN; Yu X; Xu XH; Wang YL; Zhao CQ; Luo B; Wang YK
    Virol J; 2016 Apr; 13():60. PubMed ID: 27044426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylation of ASC/TMS1 promoter is associated with poor prognosis of patients with gastric cancer.
    Wu L; Zhang C; Wang X; Ding X; Deng J; Liang H
    Clin Transl Oncol; 2016 Mar; 18(3):296-303. PubMed ID: 26260914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant promoter methylation and silencing of RASSF2A gene in cervical cancer.
    Zhang X; Ma Y; Wu Y; Lin L; Ma X; Zhang Y
    J Obstet Gynaecol Res; 2014 May; 40(5):1375-81. PubMed ID: 24605823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression level of miRNA-210-3p in cervical cancer and its prognostic potential.
    Shao MX; Qu AZ; Wang YQ; Zhong YY
    Eur Rev Med Pharmacol Sci; 2020 Jun; 24(12):6583-6588. PubMed ID: 32633346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ezrin contributes to cervical cancer progression through induction of epithelial-mesenchymal transition.
    Kong J; Di C; Piao J; Sun J; Han L; Chen L; Yan G; Lin Z
    Oncotarget; 2016 Apr; 7(15):19631-42. PubMed ID: 26933912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypermethylation of Single CpG Dinucleotides at the Promoter of CXCL13 Gene Promoting Cell Migration in Cervical Cancer.
    Ma D; Fan SB; Hua N; Li GH; Chang Q; Liu X
    Curr Cancer Drug Targets; 2020; 20(5):355-363. PubMed ID: 31899677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant expression of microRNA-26b and its prognostic potential in human cervical cancer.
    Luo M; Shen D; Wang W; Xian J
    Int J Clin Exp Pathol; 2015; 8(5):5542-8. PubMed ID: 26191262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant SOX11 promoter methylation is associated with poor prognosis in gastric cancer.
    Xu X; Chang X; Li Z; Wang J; Deng P; Zhu X; Liu J; Zhang C; Chen S; Dai D
    Cell Oncol (Dordr); 2015 Jun; 38(3):183-94. PubMed ID: 25801783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum CCAT2 as a biomarker for adjuvant diagnosis and prognostic prediction of cervical cancer.
    Cao X; Yao J; Jia M; Shen X; Zhang J; Ju S
    J Ovarian Res; 2022 Feb; 15(1):20. PubMed ID: 35115025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of eukaryotic initiation factor 5A2 (EIF5A2) is associated with cancer progression and poor prognosis in patients with early-stage cervical cancer.
    Yang SS; Gao Y; Wang DY; Xia BR; Liu YD; Qin Y; Ning XM; Li GY; Hao LX; Xiao M; Zhang YY
    Histopathology; 2016 Aug; 69(2):276-87. PubMed ID: 26799253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant methylation of the VIM promoter in uterine cervical squamous cell carcinoma.
    Lee MK; Jeong EM; Kim JH; Rho SB; Lee EJ
    Oncology; 2014; 86(5-6):359-68. PubMed ID: 24942637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicoRNA-425-5p is a potential prognostic biomarker for cervical cancer.
    Sun L; Jiang R; Li J; Wang B; Ma C; Lv Y; Mu N
    Ann Clin Biochem; 2017 Jan; 54(1):127-133. PubMed ID: 27166306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High Expression of CCDC34 Is Associated with Poor Survival in Cervical Cancer Patients.
    Liu LB; Huang J; Zhong JP; Ye GL; Xue L; Zhou MH; Huang G; Li SJ
    Med Sci Monit; 2018 Nov; 24():8383-8390. PubMed ID: 30458457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Down-regulation of PAX6 by promoter methylation is associated with poor prognosis in non small cell lung cancer.
    Zhang X; Yang X; Wang J; Liang T; Gu Y; Yang D
    Int J Clin Exp Pathol; 2015; 8(9):11452-7. PubMed ID: 26617874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant expression of ezrin and HER2 predicts distant metastasis and poor prognosis of patients with salivary gland carcinomas.
    Hashimoto K; Hayashi R; Mukaigawa T; Yamazaki M; Fujii S
    Hum Pathol; 2017 May; 63():110-119. PubMed ID: 28300573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.